214 related articles for article (PubMed ID: 33593386)
21. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
[TBL] [Abstract][Full Text] [Related]
22. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
[TBL] [Abstract][Full Text] [Related]
23. Immunochemical faecal occult blood tests have superior stability and analytical performance characteristics over guaiac-based tests in a controlled in vitro study.
Lee CS; O'Gorman P; Walsh P; Qasim A; McNamara D; O'Morain CA; Boran GP
J Clin Pathol; 2011 Jun; 64(6):524-8. PubMed ID: 21512110
[TBL] [Abstract][Full Text] [Related]
24. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
[TBL] [Abstract][Full Text] [Related]
25. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer.
Osman MA; Neoh HM; Ab Mutalib NS; Chin SF; Mazlan L; Raja Ali RA; Zakaria AD; Ngiu CS; Ang MY; Jamal R
Sci Rep; 2021 Feb; 11(1):2925. PubMed ID: 33536501
[TBL] [Abstract][Full Text] [Related]
26. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer.
Shah MS; DeSantis TZ; Weinmaier T; McMurdie PJ; Cope JL; Altrichter A; Yamal JM; Hollister EB
Gut; 2018 May; 67(5):882-891. PubMed ID: 28341746
[TBL] [Abstract][Full Text] [Related]
27. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
28. Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer.
Löwenmark T; Löfgren-Burström A; Zingmark C; Eklöf V; Dahlberg M; Wai SN; Larsson P; Ljuslinder I; Edin S; Palmqvist R
Sci Rep; 2020 Sep; 10(1):15250. PubMed ID: 32943695
[TBL] [Abstract][Full Text] [Related]
29. Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development.
Tito RY; Verbandt S; Aguirre Vazquez M; Lahti L; Verspecht C; Lloréns-Rico V; Vieira-Silva S; Arts J; Falony G; Dekker E; Reumers J; Tejpar S; Raes J
Nat Med; 2024 May; 30(5):1339-1348. PubMed ID: 38689063
[TBL] [Abstract][Full Text] [Related]
30. Guaiac faecal occult blood screening in individuals younger than 50 years of age.
Zalts R; Moadi Z; Avizohar O; Leiba R; Half E; Karban A
Eur J Cancer Prev; 2017 May; 26(3):189-194. PubMed ID: 27167151
[TBL] [Abstract][Full Text] [Related]
31. Analysis of an Indian colorectal cancer faecal microbiome collection demonstrates universal colorectal cancer-associated patterns, but closest correlation with other Indian cohorts.
Bose M; Wood HM; Young C; ; Quirke P; Seshadri RA
BMC Microbiol; 2023 Mar; 23(1):52. PubMed ID: 36858965
[TBL] [Abstract][Full Text] [Related]
32. Identification of colorectal cancer progression-associated intestinal microbiome and predictive signature construction.
Liu J; Huang X; Chen C; Wang Z; Huang Z; Qin M; He F; Tang B; Long C; Hu H; Pan S; Wu J; Tang W
J Transl Med; 2023 Jun; 21(1):373. PubMed ID: 37291572
[TBL] [Abstract][Full Text] [Related]
33. Tests and investigations for colorectal cancer screening.
Carroll MR; Seaman HE; Halloran SP
Clin Biochem; 2014 Jul; 47(10-11):921-39. PubMed ID: 24769265
[TBL] [Abstract][Full Text] [Related]
34. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer.
Yang Y; Misra BB; Liang L; Bi D; Weng W; Wu W; Cai S; Qin H; Goel A; Li X; Ma Y
Theranostics; 2019; 9(14):4101-4114. PubMed ID: 31281534
[No Abstract] [Full Text] [Related]
35. Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer.
Zhang S; Kong C; Yang Y; Cai S; Li X; Cai G; Ma Y
Theranostics; 2020; 10(25):11595-11606. PubMed ID: 33052235
[No Abstract] [Full Text] [Related]
36. Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England.
Benton SC; Piggott C; Blyuss O; Li SJ; Mathews C; Carroll M; Duffy S
J Med Screen; 2021 Dec; 28(4):426-432. PubMed ID: 33983066
[TBL] [Abstract][Full Text] [Related]
37. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
[TBL] [Abstract][Full Text] [Related]
38. Screening for colorectal neoplasias with fecal occult blood tests: false-positive impact of non-dietary restriction.
Roslani AC; Abdullah T; Arumugam K
Asian Pac J Cancer Prev; 2012; 13(1):237-41. PubMed ID: 22502676
[TBL] [Abstract][Full Text] [Related]
39. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
[TBL] [Abstract][Full Text] [Related]
40. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
Bretagne JF; Carlo A; Piette C; Rousseau C; Cosson M; Lièvre A
Br J Cancer; 2021 Nov; 125(11):1494-1502. PubMed ID: 34511603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
